Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study

Sangheun Lee, Beom Kyung Kim, Seung Up Kim, Soo Young Park, Ja Kyung Kim, Hyun Woong Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Won Young Tak, Young Oh Kweon, Jung Il Lee, Kwan Sik Lee, Hyung Joon Kim, Kwang Hyub Han

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background and Aim: Sorafenib is recommended as a standard treatment for advanced hepatocellular carcinoma (HCC). The efficacy and safety of sorafenib as a first-line therapy in Korean patients with advanced HCC were investigated. Methods: From 2007 to 2012, 86 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C) treated with sorafenib as a first-line therapy were enrolled from five tertiary hospitals. Predictors of overall survival (OS) and progression-free survival (PFS) were analyzed. Results: The median age was 59.5 years, and 71 (82.6%) were males; 57 (66.3%) patients were in Child-Pugh class A. The median OS and PFS were 5.0 (range 4.0-5.9) and 3.2 (range 2.6-3.7) months, respectively. Regarding OS, Child-Pugh class A (6.0 vs 2.8 months), tumor diameter <5cm (6.0 vs 4.3 months), baseline α-fetoprotein <200ng/mL (5.8 vs 4.1 months), and the advent of hand-foot-skin reaction of ≥grade 2 (5.9 vs 4.0 months) were independent favorable predictors (all P<0.05). Similarly, regarding PFS, Child-Pugh class A (4.3 vs 2.1 months), tumor diameter <5cm (3.9 vs 2.8 months), baseline α-fetoprotein <200ng/mL (5.6 vs 2.8 months), and the advent of hand-foot-skin reaction of ≥grade 2 (4.5 vs 2.6 months) were independent favorable predictors (all P<0.05). All toxicities during sorafenib treatment were manageable. Conclusions: Because the efficacy of sorafenib seems marginal in Korean patients with treatment-naïve HCC, how to select candidates with favorable outcomes should be further investigated.

Original languageEnglish
Pages (from-to)1463-1469
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume29
Issue number7
DOIs
Publication statusPublished - 2014 Jul

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study'. Together they form a unique fingerprint.

  • Cite this